ONJ Osteonecrosis of the Jaw in BisphosphonateTreated Cancer Patients - PowerPoint PPT Presentation

1 / 14
About This Presentation
Title:

ONJ Osteonecrosis of the Jaw in BisphosphonateTreated Cancer Patients

Description:

... (Zometa) is approved for the treatment of any advanced malignancy involving bone ... The clinical identification of ONJ is usually made on the basis of visual ... – PowerPoint PPT presentation

Number of Views:258
Avg rating:3.0/5.0
Slides: 15
Provided by: lsmo4
Category:

less

Transcript and Presenter's Notes

Title: ONJ Osteonecrosis of the Jaw in BisphosphonateTreated Cancer Patients


1
ONJ (Osteonecrosis of the Jaw) in
Bisphosphonate-Treated Cancer Patients
2
  • Bisphosphonates effectively manage bone
    complications from cancer
  • Approved for treatment of malignant bone disease
    from solid tumors and multiple myeloma
  • Zoledronic acid (Zometa) is approved for the
    treatment of any advanced malignancy involving
    bone

3
  • ? Common adverse events
  • - Flu-like symptoms
  • - Fever
  • - Myalgias/ Arthralgias
  • ? Uncommon adverse events
  • - Renal-function effects
  • - Osteonecrosis of the jaw

4
ONJ
  • Etiology and pathogenesis are not well
    characterized
  • The clinical identification of ONJ is usually
    made on the basis of visual inspection and/or
    radiographic appearance

5
(No Transcript)
6
  • Risk Factors for ONJ
  • Periodontal disease
  • Dento-alveolar surgery
  • Oral trauma
  • Corticosteroid therapy
  • Immuno-compromised state

7
Recommendations for the Management of ONJ
  • Prevention of ONJ
  • Prior to treatment with bisphosphonates
  • Dental exam with appropriate preventive
    dentistry
  • Remove abscessed teeth, and teeth with poor
    long-term prognosis
  • Educate patients on oral hygiene and signs
    and symptoms of ONJ

8
  • During bisphosphonate treatment
  • Seek dental maintenance care at least every
    6 months
  • Avoid invasive dental procedures if possible

9
  • In case of ONJ
  • Refer to dental professional as soon as
    possible
  • Reassess benefit/risk of continued
    bisphosphonate therapy
  • No prospective data exist to withhold
    therapyConservative management

10
  • ONJ Outcomes
  • Emerging data indicate that stability /
    improvement of lesions occurs in the majority of
    patients with conservative management
  • With preventive measures and conservative
    management, deterioration occurs only in a
    minority of patients

11
ONJ personal clinical case
V.H.52 year old man receiving IV Biphosphonate as
maintenance therapy for Multiple Myeloma
ONJ healing after 3 months
ONJ after two years of Biphosphonate therapy
12
(No Transcript)
13
  • Summary
  • - ONJ is an uncommon event
  • - Most patients can be managed conservatively
    according to guidelines with minimal impact on
    quality of life
  • - Ongoing studies will increase the
    understanding of ONJ

14
  • THANK YOU
Write a Comment
User Comments (0)
About PowerShow.com